Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Valneva SE experienced a trading volume of 57,277 shares, a decrease from the previous day's 60,005 shares, with its stock price currently at $7.55, down from $7.68.
• Wall Street analysts have mixed forecasts for Valneva, with HC Wainwright maintaining a "buy" rating and a price target of $17, while Guggenheim lowered its target from $15 to $14.
• Valneva reported a quarterly earnings beat with an EPS of ($0.13), exceeding estimates, and posted revenues of $51.79 million, surpassing expectations of $41.80 million.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) saw an uptick in trading volume on Monday . 57,277 shares traded hands during trading, a decline of 5% from the previous session's volume of 60,005 shares.The stock last traded at $7.55 and had previously closed at $7.68.

Analyst Upgrades and Downgrades

VALN has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim dropped their target price on shares of Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, May 8th.

Valneva Trading Down 1.8%

The business's 50-day simple moving average is $6.26 and its 200-day simple moving average is $6.42. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70. The company has a market capitalization of $614.38 million, a price-to-earnings ratio of -6.07 and a beta of 1.74.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.27. The business had revenue of $51.79 million for the quarter, compared to analyst estimates of $41.80 million. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. On average, research analysts expect that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN raised its stake in shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 246,766 shares of the company's stock after buying an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 at the end of the most recent reporting period. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.